Investor Relations

Website Notice Block

Corporate Profile

MediWound is a biopharmaceutical company that develops, manufactures, and commercializes novel, cost effective, non-surgical bio-therapeutic solutions for tissue repair and regeneration. Our strategy leverages our enzymatic technology platform, focused on next-generation bioactive therapies for burn care, wound care and tissue repair.

Change
Volume
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events
Investor Presentation
Quarterly Results

Press Releases

MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update

March 16, 2023

2022 total revenues of $26.5 million FDA approval of NexoBrid ® in December 2022 ; U.S. commercial availability expected in the second quarter of 2023 EscharEx ® Phase III protocol design is under review by the FDA; study to be initiated in the second half of 2023 C ash position of $66 million ,

MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer

March 16, 2023

YAVNE, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms.

View All Press Releases  ///